Although lanperisone can effectively enhance ROS production mediated by the RAS/MEK/ERK signaling pathway to induce ferroptosis due to KRAS gene mutation in embryonic fibroblasts, it displays less competency than erastin in resisting against KRAS-driven tumor vitality (Shaw et al., 2011). The gene discussed is KRAS; the disease is neoplasm.